KalVista Pharmaceuticals, Inc. announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged 2 to 11 years across seven countries in North America, Europe and Asia. KONFIDENT-K ID will collect safety, pharmacokinetic, and efficacy data for each patient for up to one year and will feature a proprietary pediatric oral disintegrating tablet (ODT) formulation of sebetralstat.

If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 - 11 years, and only the second FDA-approved on-demand therapy of any type in this population.